Clinical Trials Arena on MSN2d
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
Morningstar3d
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene ... via intravesical instillation using Ractigen's proprietary LiCO™ delivery technology, RAG-01 ...